Efficacy of Splenectomy in Treating Refractory Autoimmune Hemolytic Anemia Linked to Systemic Lupus Erythematosus: A Case Study with Mechanistic Analysis - Takeaways - MDSpire

Efficacy of Splenectomy in Treating Refractory Autoimmune Hemolytic Anemia Linked to Systemic Lupus Erythematosus: A Case Study with Mechanistic Analysis

  • By

  • Xiaoli Pan

  • Juan Chen

  • Chunyan Li

  • Yupei Lin

  • Yu Wang

  • Jingqiao Tian

  • Mei Tian

  • Anmao Li

  • April 28, 2026

  • 0 min

Share

  • 1

    Splenectomy is considered a third-line treatment for refractory autoimmune hemolytic anemia (AIHA) in systemic lupus erythematosus (SLE) patients.

  • 2

    A case study reported a patient with refractory SLE-associated AIHA who achieved sustained hematologic improvement after undergoing splenectomy.

  • 3

    The spleen was identified as a major site of erythrocyte destruction and a key organ in sustaining abnormal immune responses in the patient.

  • 4

    Multiple treatment modalities, including glucocorticoids and rituximab, failed to improve the patient's condition prior to splenectomy.

  • 5

    Positive IFI44L methylation findings supported the SLE-related immune background in the patient, highlighting the complexity of SLE-associated AIHA.

Original Source(s)

Efficacy of Splenectomy in Treating Refractory Autoimmune Hemolytic Anemia Linked to Systemic Lupus Erythematosus: A Case Study with Mechanistic Analysis

  • by Xiaoli Pan, Juan Chen, Chunyan Li, Yupei Lin, Yu Wang, Jingqiao Tian, Mei Tian, Anmao Li

  • April 28, 2026

Related Content

Research advances in connective tissue disease-associated pulmonary arterial hypertension with an emphasis on the Chinese population

Connective tissue diseases combined with chronic myelomonocytic leukemia and myelofibrosis: a case report and literature review

Immune regulation and cell metabolism in B cell subsets in patients with systemic lupus erythematosus